First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Table 3 Ongoing clinical trials evaluating new anti-HER2 molecules combined with hormone therapy in first-line setting

Trial	Phase	Treatment	Primary Objective
PERTAIN	II	Trastuzumab + Pertuzumab + AI vs Trastuzumab + AI	PFS
DETECT V/CHEVENDO	III	Trastuzumab + Pertuzumab + CT vs Trastuzumab + Pertuzumab + HT^a	Safety
1303GCC	II	Trastuzumab + Pertuzumab vs Trastuzumab + Pertuzumab + Eribulin vs Trastuzumab + Pertuzumab + HT ^b	ORr

AI aromatase hinibitor, CT chemotherapy (docetaxel, paclitaxel, capecitabine, vinorelbine), ^aHT: Hormonal Therapy (tamoxifen, fulvestrant, letrozole, exemestane or anastrozole); ^bHT: Hormonal Therapy (anastrozolo or fulvestrant); PFS: Progression Free Survival; ORr: Overall Response rate

ISSN: 1756-9966